--- title: "Advanced Melanoma Mirdametinib CPMC24-MEL01 | Sutter Health" description: "A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation (CPMC24-MEL01)" url: "https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-mirdametinib-cpmc24-mel01-2036974828" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Advanced Melanoma Mirdametinib CPMC24-MEL01 # Advanced Melanoma Mirdametinib CPMC24-MEL01 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-mirdametinib-cpmc24-mel01-2036974828#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07237100). #### Locations - San Francisco #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation (CPMC24-MEL01) ![Kevin B Kim, M.D.](https://dyn.mktgcdn.com/p/c5YP2PezO8WGhQo-AyMNM4jgZenkBbfA9R6zjGEliTY/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Kevin B Kim, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/kevin-b-kim-md-1049681162) ## Email us to enroll - [Email San Francisco](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Advanced%20Melanoma%20Mirdametinib%20CPMC24-MEL01%20in%20San%20Francisco&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Advanced Melanoma Ignyte-3](https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-ignyte-3-1095539355) Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment **Status:** Open to Enrollment - Clinical trial ### [Advanced Cervical Cancer NRG GY037](https://www.sutterhealth.org/research/clinical-trials/advanced-cervical-cancer-nrg-gy037-2097344123) A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer **Status:** Open to Enrollment - Clinical trial ### [Advanced Staged Cancer Targeted Therapy ASCO TAPUR](https://www.sutterhealth.org/research/clinical-trials/targeted-agent-and-profiling-utilization-registry-tapur-st-1049141787) Targeted Agent and Profiling Utilization Registry (TAPUR) Study **Status:** Open to Enrollment - Clinical trial ### [Adverse Effects of Chemotherapy Shengbai Solution](https://www.sutterhealth.org/research/clinical-trials/adverse-effects-of-chemotherapy-shengbai-solution-1097505286) A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy **Status:** Open to Enrollment - Clinical trial ### [Acute Myeloid Leukemia Dental Wipes COG ACCL2531](https://www.sutterhealth.org/research/clinical-trials/acute-myeloid-leukemia-dental-wipes-cog-accl2531-2099128841) A Randomized Double-Blinded Trial of Xylitol Dental Wipes for the Prophylaxis of Bloodstream Infections From Oral Organisms in Pediatric Patients With Acute Myeloid Leukemia **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-mirdametinib-cpmc24-mel01-2036974828#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Advanced Melanoma Mirdametinib CPMC24-MEL01"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-mirdametinib-cpmc24-mel01-2036974828#medicalwebpage","name":"Advanced Melanoma Mirdametinib CPMC24-MEL01","description":"A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation (CPMC24-MEL01)","url":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-mirdametinib-cpmc24-mel01-2036974828","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-mirdametinib-cpmc24-mel01-2036974828#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-mirdametinib-cpmc24-mel01-2036974828#breadcrumblist"},"mentions":[{"@type":"Person","name":"Kevin B Kim, M.D.","url":"https://www.sutterhealth.org/research/investigators/kevin-b-kim-md-1049681162","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-mirdametinib-cpmc24-mel01-2036974828#medicaltrial","name":"Advanced Melanoma Mirdametinib CPMC24-MEL01","alternateName":"A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation (CPMC24-MEL01)","url":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-mirdametinib-cpmc24-mel01-2036974828","description":"A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation (CPMC24-MEL01)","identifier":"NCT07237100","code":{"@type":"MedicalCode","codeValue":"NCT07237100","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT07237100","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Skin Cancer/Melanoma"}],"studyLocation":[{"@type":"AdministrativeArea","name":"San Francisco"}]} ```